Pfizer, Trump strike drug pricing deal

President Trump and Pfizer have reached a sweeping deal aimed at cutting drug costs for Americans while giving the pharmaceutical company tariff relief, balancing political pressure with business incentives.

Under the agreement, Pfizer will join a new government-run platform named TrumpRx.gov. Through this portal, U.S. patients will be able to purchase many of Pfizer’s generic and primary-care medicines, plus certain specialty brands, at deep discounts. The company says these discounts will average around 50 percent, and for some drugs reach as much as 85 percent.

A central element of the deal is “most-favored-nation” (MFN) pricing: Pfizer will sell its medicines to Medicaid at the same (lowest) net prices it offers in other developed countries. It also pledges that newly launched drugs will be priced in parity with key foreign markets.

In exchange for these concessions on pricing, Pfizer receives a three-year exemption from pharmaceutical tariffs—so long as it commits to significant investment in U.S. infrastructure, research, and manufacturing. The company has pledged about $70 billion toward those efforts.

Trump framed the deal as a win for ordinary Americans, saying it would help reduce Medicaid costs and make prescription drugs more affordable. The White House also cautioned that further agreements with other drugmakers would follow.

From Pfizer’s perspective, the deal offers predictability under tariff threats, while giving it a pathway to invest in U.S. production. But the real-world impact remains uncertain: how much of those discounts reach insured patients or those with private coverage is unclear, and critics warn that shifting costs or hidden conditions could dampen the benefits.

In short: the agreement is a high-stakes gambit — Trump gains a headline victory on drug pricing, Pfizer gains tariff protection and investment incentives — but whether everyday Americans will see meaningful savings remains to be seen.

Source: POLITICO